CoChat
Sign Up
Cited by 103Nail Diseases and TreatmentsDermatology and Skin DiseasesHair Growth and Disorders

Dermatite seborreica

Open access
Sampaio, Ana Luisa Sobral Bittencourt, Mameri, Ângela Cristina Akel, Vargas, Thiago Jeunon de Sousa, Ramos-e-Silva, Marcia, Nunes, Amanda Pedreira, Carneiro, Sueli Coelho da Silva·2011·Anais Brasileiros de Dermatologia
DOI 10.1590/s0365-05962011000600002
Open this paper in CoChat — free accountOpen PDF

Abstract

A dermatite seborreica é uma doença eritêmato-escamativa de caráter crônico-recidivante que acomete entre 1 e 3% da população geral dos Estados Unidos. Possui dois picos de incidência - o primeiro, durante os três primeiros meses de vida, e o segundo, a partir da puberdade, atingindo seu ápice entre os 40 e 60 anos de idade. Os indivíduos HIV positivos têm maior prevalência da doença, que apresenta maior intensidade e tendência à refratariedade ao tratamento. Doenças neurológicas e outras doenças crônicas também estão associadas ao desenvolvimento da dermatite seborreica. Como mecanismo fisiopatogênico, reconhece-se que o fungo Malassezia sp., presente na pele de indivíduos suscetíveis, leve a uma irritação não-imunogênica a partir da produção de metabólitos à base de ácidos graxos insaturados deixados na superfície cutânea. Este artigo faz uma revisão da literatura sobre dermatite seborreica, com ênfase nos aspectos imunogenéticos, formas clínicas e tratamento.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/s0365-05962011000600002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SD incidence peaks during three age periods: the first three months of life, puberty, and adulthood with an apex at 40 to 60 years of age.

    “Its incidence peaks during three age periods - in the first three months of life, during puberty, and in adulthood with an apex at 40 to 60 years of age [1–4].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [3]

    The paper’s Abstract (page unavailable) states that seborrheic dermatitis has two incidence peaks, not three: one in the first three months of life and a second beginning at puberty that reaches its apex at ages 40–60. It does not describe puberty and adulthood as separate peaks. (LLM, conf=0.90)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

  • Incidence of SD in the general adult population is 1-3%.

    “Incidence is 1–3% of the general adult population [3,9].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [3]

    The Abstract reports that seborrheic dermatitis affects 1–3% of the general US population. It does not give that figure specifically for adults or identify it as an incidence rate; it separately describes two age-related peaks in incidence. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • SD may be associated with sex hormones such as androgens.

    “Men are affected more frequently than women (3.0% vs. 2.6%) in all age groups, suggesting that SD may be associated with sex hormones such as androgens [1,3,8].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [3]

    In the paper’s continuing-education questions (section labeled “Medicações tópicas,” page unavailable), an item links seborrheic dermatitis with sex hormones, citing its occurrence in newborns and return in adolescence. The copy does not specifically identify androgens as the hormones involved; its treatment discussion mentions antiandrogenic effects of antifungals only as a debated possibility. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • In immune-suppressed patients, SD is often more extensive, intense, and refractory to treatment.

    “In immune-suppressed patients, SD is often more extensive, intense, and refractory to treatment [3,26,30].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [3]

    The “Dermatite seborreica e HIV” section says seborrheic dermatitis in HIV-positive patients can be more extensive, intense, and refractory to conventional treatment. It does not establish that this is often the case across immune-suppressed patients generally. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • Systemic therapy is needed only in widespread lesions and in cases that do not respond to topical treatment.

    “Systemic therapy is needed only in widespread lesions and in cases that do not respond to topical treatment [3,26].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [3]

    The “Medicações tópicas” section says oral medicines can be used mainly for extensive seborrheic dermatitis that is refractory to topical medicines. This supports systemic treatment in those circumstances, but does not say it is needed or that its use is limited to them. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 97

  1. Schechtman RC, Midgley G, Hay RJ. HIV disease and Malassezia yeasts: a quantitative study of patients presenting with seborrhoeic dermatitis. Br J Dermatol. 1995;133:694-8.
  2. Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatology. 2004;208:89-93.
  3. Inamadar AC PA. The genus Malassezia and human disease. Indian J Dermatol Venereol Leprol. 2003;69:265-70.
  4. Moore M. Dermatite seborreica: cultivo do organismo caudador da dermatite produzida experimentalmente. An Bras Dermatol. 1936;11:7-10.
  5. Unna P. Das seborrhoische Ekzem. Monatsschr Prakt Dermatol. 1897;6:827-46.
  6. Leone R. [Presence and significance of Pityrosporon ovale in pityriasis of the scalp, in figured seborrheic eczema and in various squamous dermatoses. Note III. Cultural, biological and biochemical properties of Pityrosporon ovale, with special reference to the affinity for lipidic substances.]. Minerva Dermatol. 1952;27:123-7.
  7. Leone R. [Presence and significance of Pityrosporon ovale in pityriasis of the scalp, in figured seborrheic eczema and in various squamous dermatoses. Note I. Quantitative research on the presence of Pityrosporon ovale in pityriasis of the scalp, in figured seborrheic eczema and in various squamous dermatoses.]. Minerva Dermatol. 1952;27:93-9.
  8. Palacky AF, Strycek R. [Modifications in blood proteins in erythroderma and seborrhoeic dermatitis and their relation to biotin deficiency]. Pediatr Listy.1950;5:270-3.
  9. Gougerot H, Grupper C, Plas G. [Cutaneous-mucosal ariboflavinosis; rosacea of cornea and medio-facial seborrheic dermatitis.]. Bull Soc Fr Dermatol Syphiligr. 1950;57:277-80.
  10. Andrews GC, Post CF, Domonkos AN. Seborrheic dermatitis; supplemental treatment with vitamin B12. N Y State J Med. 1950;50:1921-5.
  11. Kiessling W. [Clinical results with internal and intramuscular administration of biotin]. Dermatol Wochenschr. 1951;124:1246-9.
  12. Treger J, Moys A, Muzikova M. [Effect of intracutaneous biotin in eczema seborrhoe- icum]. Bratisl Lek Listy. 1951;31:562-8.
  13. Avcin M. [Dermatitis seborrheica and biotin deficiency in infants]. Zdrav Vestn.1952;21:15-21.
  14. Schreiner AW, Rockwell E, Vilter RW. A local defect in the metabolism of pyridoxine in the skin of person with seborrheic dermatitis of the "sicca" type. J Invest Dermatol. 1952;19:95-6.
  15. Nisenson A. Seborrheic dermatitis of infants and Leiners's disease: a biotin deficiency. J Pediatr. 1957;51:537-48.
  16. Nisenson A, Barness LA. Treatment of seborrheic dermatitis with biotin and vitamin B complex. J Pediatr. 1972;81:630-1.
  17. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74:125-30.
  18. Sudan BJ. Nicotine skin patch treatment and adverse reactions: skin irritation, skin sensitization, and nicotine as a hapten. J Clin Psychopharmacol. 1995;15:145-6.
  19. Sudan BJ. Abrogation of facial seborrhoeic dermatitis with homoeopathic high dilutions of tobacco: a new visible model for Benveniste's theory of 'Memory of water'. Med Hypotheses. 1993;41:440-4.
  20. Sudan BJ. Ketoconazole, leukotrienes, Paf-acether and nicotine as a hapten: the possible aetiology of seborrhoeic dermatitis. Med Hypotheses. 1987;23:33-8.
  21. Sudan BJ. Seborrhoeic dermatitis induced by nicotine of horsetails (Equisetum arvense L.). Contact Dermatitis. 1985;13:201-2.
  22. Sudan BJ, Brouillard C, Sterboul J, Sainte-Laudy J. Nicotine as a hapten in seborrhoeic dermatitis. Contact Dermatitis. 1984;11:196-7.
  23. Stone OJ. Seborrheic dermatitis--hyperreactive inflammation to saprophytes. Dermatol Int. 1968;7:14-6.
  24. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson's disease: a survey of (im)possible links. Med Hypotheses. 2003;60:907-11.
  25. Pierard GE. Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology. 2003;206:187-8.
  26. Parish LC. L-dopa for seborrheic dermatitis. N Engl J Med. 1970;283:879.
  27. Appenzeller O, Harville D. Effect of L-dopa on seborrhea of Parkinsonism. Lancet. 1970;2:311-2.
  28. Burton JL, Shuster S. Effect of L-dopa on seborrhoea of Parkinsonism. Lancet. 1970;2:311.
  29. Burton JL, Shuster S. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970;2:19-20.
  30. Potter J, Wyburn-Mason R. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970;2:660.
  31. Wyburn-Mason R. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970;2:154.
  32. Martignoni E, Godi L, Pacchetti C, Berardesca E, Vignoli GP, Albani G, et al. Is seborrhea a sign of autonomic impairment in Parkinson's disease? J Neural Transm. 1997;104:1295-304.
  33. Binder RL, Jonelis FJ. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol. 1983;119:473-5.
  34. Binder RL, Jonelis FJ. Seborrheic dermatitis: a newly reported side effect of neuroleptics. J Clin Psychiatry. 1984;45:125-6.
  35. Moris G, Ribacoba R, Solar DN, Vidal JA. SUNCT syndrome and seborrheic dermatitis associated with craneosynostosis. Cephalalgia. 2001;21:157-9.
  36. Rocha N, Velho G, Horta M, Martins A, Massa A. Cutaneous manifestations of familial amyloidotic polyneuropathy. J Eur Acad Dermatol Venereol. 2005;19:605-7.
  37. Rubin-Asher D, Zeilig G, Klieger M, Adunsky A, Weingarden H. Dermatological findings following acute traumatic spinal cord injury. Spinal Cord. 2005;43:175-8.
  38. Tronnier H. [On an unilaterally localized seborrhoic eczema in syringomyelia.]. Z Haut Geschlechtskr. 1964;37:207-17.
  39. Bettley FR, Marten RH. Unilateral seborrheic dermatitis following a nerve lesion. AMA Arch Derm. 1956;73:110-5.
  40. Chen TM, Fitzpatrick JE. Unilateral seborrheic dermatitis after decompression of Chiari I malformation and syringomyelia J Am Acad Dermatol. 2006;55:356-7.
  41. Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Genet. 1996;50:317-20.
  42. Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol. 2007;24:317-20.
  43. Tager A, Berlin C, Schen RJ. Seborrhoeic Dermatitis in Acute Cardiac Disease. Br J Dermatol. 1964;76:367-9.
  44. Barba A, Piubello W, Vantini I, Caliari S, Cocchetto R, Vallaperta P, et al. Skin lesions in chronic alcoholic pancreatitis. Dermatologica. 1982;164:322-6.
  45. Rao GS. Cutaneous changes in chronic alcoholics. Indian J Dermatol Venereol Leprol. 2004;70:79-81.
  46. Naegeli B. [A case from practice (218). Alcoholic sensorimotor polyneuropathy and myopathy in chronic alcoholism. Seborrheic dermatitis]. Schweiz Rundsch Med Prax. 1991;80:650-2.
  47. Parish LC, Fine E. Alcoholism and skin disease. Int J Dermatol. 1985;24:300-1.
  48. Moore M, Kile RL. Pityrosporum ovalis as a causative agent of seborrheic dermatitis. Science. 1935;81:277-8.
  49. Aspiroz MC, Moreno LA, Rubio MC. [Taxonomy of Malassezia furfur: state of the art]. Rev Iberoam Micol. 1997;14:147-9.
  50. Guého E MG, Guillot J. The genus Malassezia with description of four new species. Antonie Van Leeuwenhoek. 1996;69:337-55.
  51. Goodfield MJ, Saihan EM, Crowley J. Experimental folliculitis with Pityrosporum orbiculare: the influence of host response. Acta Derm Venereol. 1987;67:445-7.
  52. Faergemann J. Pityrosporum infections. J Am Acad Dermatol. 1994;31:S18-20.
  53. Faergemann J. Pityrosporum ovale and skin diseases. Keio J Med. 1993;42:91-4.
  54. Terui T, Kudo K, Tagami H. [Cutaneous immune and inflammatory reactions to Malassezia furfur]. Nihon Ishinkin Gakkai Zasshi. 1999;40:63-7.
  55. Faergemann J, Fredriksson T. Tinea versicolor with regard to seborrheic dermatitis. An epidemiological investigation. Arch Dermatol. 1979;115:966-8.
  56. McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol. 1975;64:401-5.
  57. Bergbrant IM, Faergemann J. Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm Venereol. 1989;69:332-5.
  58. Bourlond A, Votion V, Armijo F, Minne G. [Pityrosporum ovale in keratotic lesions of seborrheic areas]. Ann Dermatol Venereol. 1984;111:1081-5.
  59. Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol. 2000;38:337-41.
  60. Nakabayashi A. [Identification of causative species in malassezia-associated dermatoses]. Nihon Ishinkin Gakkai Zasshi. 2002;43:65-8.
  61. Rendic E, Diaz C, Fich F. [Characterization of species of the gender Malassezia in patients with seborrheic dermatitis and subjects without skin lesions]. Rev Med Chil. 2003;131:1295-300.
  62. Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol. 2001;39:243-51.
  63. Gaitanis G, Velegraki A, Alexopoulos EC, Chasapi V, Tsigonia A, Katsambas A. Distribution of Malassezia species in pityriasis versicolor and seborrhoeic dermatitis in Greece. Typing of the major pityriasis versicolor isolate M. globosa. Br J Dermatol. 2006;154:854-9.
  64. Tajima M, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia Sampaio ALB, Mameri A, Jeunon T, Ramos-e-Silva M, Nunes AP, Carneiro S microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol. 2008;128:345-51.
  65. Nakabayashi A, Sei Y. [Relationship between Malassezia Yeast and Infantile Seborrhoeic Dermatitis]. Nihon Ishinkin Gakkai Zasshi. 2001;42:218-20.
  66. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh). 1991;167:1-36.
  67. Bergbrant IM, Faergemann J. The role of Pityrosporum ovale in seborrheic dermatitis. Semin Dermatol. 1990;9:262-8.
  68. DeAngelis YM, Saunders CW, Johnstone KR, Reeder NL, Coleman CG, Kaczvinsky JR Jr, et al. Isolation and expression of a Malassezia globosa lipase gene, LIP1. J Invest Dermatol. 2007;127:2138-46.
  69. Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc. 2005;10:194-7.
  70. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum yeasts. Curr Top Med Mycol. 1995;6:95-112.
  71. Cowley NC, Farr PM, Shuster S. The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol. 1990;122:71-6.
  72. Wishner AJ, Teplitz ED, Goodman DS. Pityrosporum, ketoconazole, and seborrheic dermatitis. J Am Acad Dermatol. 1987;17:140-1.
  73. Hay RJ, Graham-Brown RA. Dandruff and seborrhoeic dermatitis: causes and management. Clin Exp Dermatol. 1997;22:3-6.
  74. Dawson TL Jr. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc. 2007;12:15-9.
  75. Braun-Falco O, Heilgemeir GP, Lincke-Plewig H. [Histological differential diagnosis of psoriasis vulgaris and seborrheic eczema of the scalp]. Hautarzt. 1979;30:478-83.
  76. Houck G, Saeed S, Stevens GL, Morgan MB. Eczema and the spongiotic dermatoses: a histologic and pathogenic update. Semin Cutan Med Surg. 2004;23:39-45.
  77. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 1998;139:254-63.
  78. Ashbee HR, Fruin A, Holland KT, Cunliffe WJ, Ingham E. Humoral immunity to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp Dermatol. 1994;3:227-33.
  79. Neuber K, Kroger S, Gruseck E, Abeck D, Ring J. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res.1996;288:532-6.
  80. Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol. 2001;116:769-73.
  81. Ashbee HR, Ingham E, Holland KT, Cunliffe WJ. Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp Dermatol. 1994;3:106-12.
  82. Passi S, Morrone A, De Luca C, Picardo M, Ippolito F. Blood levels of vitamin E, polyunsaturated fatty acids of phospholipids, lipoperoxides and glutathione peroxi- dase in patients affected with seborrheic dermatitis. J Dermatol Sci. 1991;2:171-8.
  83. Ianosi S, Stoicescu I, Ianosi G, Neagoe D, Georgescu CV. The study of CD20 and CD45.Ro antibodies in the inflammatory infiltrate involved in acne and seborrheic dermatitis. Rom J Morphol Embryol. 2007;48:285-9.
  84. Tsuji K, Nose Y, Ito M, Ozala A, Matsuo I. HLA antigens and susceptibility to psoriasis vulgaris in a non-Caucasian population. Tissue antigens. 1976;8:29-33.
  85. Fritsch PO, Reider N. Other Eczematous Eruptions. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. Spain: Mosby Elsevier; 2008. p.197-200.
  86. Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol.. 2003;139:318-22.
  87. Misery L, Touboul S, Vincot C, Dutray S, Rolland-Jacob G, Consoli SG, et al. [Stress and seborrheic dermatitis]. Ann Dermatol Venereol. 2007;134:833-7.
  88. Peyri J, Lleonart M. [Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis]. Actas Dermosifiliogr. 2007;98:476-82.
  89. Sarkar R, Sharma RC, Koranne RV, Sardana K. Erythroderma in children: a clinico- etiological study. J Dermatol.. 1999;26:507-11.
  90. Sarkar R, Garg VK. Erythroderma in children. Indian J Dermatol Venereol Leprol. 2010;76:341-7.
  91. Al-Dhalimi MA. Neonatal and infantile erythroderma: a clinical and follow-up study of 42 cases. J Dermatol. 2007;34:302-7.
  92. Cherny S, Mraz S, Su L, Harvell J, Kohler S. Heteroduplex analysis of T-cell receptor gamma gene rearrangement as an adjuvant diagnostic tool in skin biopsies for ery throderma. J Cutan Pathol. 2001;28:351-5.
  93. Yamamoto T, Tsuboi R. Interleukin-2-induced seborrhoeic dermatitis-like eruption. J Eur Acad Dermatol Venereol. 2008;22:244-5.
  94. Valia RG. Etiopathogenesis of seborrheic dermatitis. Indian J Dermatol Venereol Leprol. 2006;72:253-5.
  95. Berger RS, Stoner MF, Hobbs ER, Hayes TJ, Boswell RN. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol. 1988;19:298-303. 100. Eisenstat BA, Wormser GP. Seborrheic dermatitis and butterfly rash in AIDS. N Engl J Med. 1984;311:189. 101. Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. J Am Acad Dermatol. 1986;14:242-8. 102. Blanes M BI, Merino E, Portilla J, Sánchez-Payá J, Betlloch I. Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection. Actas Dermosifiliogr. 2010;101:702-9. 103. Hakansson C, Faergemann J, Lowhagen GB. Studies on the lipophilic yeast Pityrosporum ovale in HIV-seropositive and HIV-seronegative homosexual men. Acta Derm Venereol. 1988;68:422-6. 104. Schoefer H, Sachs DL, Ochsendorf F. HIV-associated skin and mucocutaneous dis eases. In: Hoffman C, Rockstroh JK, Kamps BS, editors. HIV medicine. 15th ed. Paris, Cagliari, Wuppertal: Flying Publisher: 2007. p.596. 105. Rincón S, Celis A, Sopó L, Motta A, Cepero de García MC. Malassezia yeast species isolated from patients with dermatologic lesions. Biomedica. 2005;25:189-95. 106. Vidal C, Girard PM, Dompmartin D, Bosson JL, Mettra C, Groslambert P, et al. Seborrheic dermatitis and HIV infection. Qualitative analysis of skin surface lipids in men seropositive and seronegative for HIV. J Am Acad Dermatol. 1990;23:1106-10. 107. Passi S, Picardo M, Morrone A, De Luca C, Ippolito F. Skin surface lipids in HIV sero- positive and HIV sero-negative patients affected with seborrheic dermatitis. J Dermatol Sci. 1991;2:84-91. 108. Nnoruka EN, Chukwuka JC, Anisuiba B. Correlation of mucocutaneous manifesta- tions of HIV/AIDS infection with CD4 counts and disease progression. Int J Dermatol. 2007;46 Suppl 2:14-8. 109. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med. 2004;5:50-4. 110.
  96. Bonnetblanc JM, De Prost Y, Bazex J, Maignan-Gayrard P. [Treatment of seborrheic dermatitis with benzoyl peroxide]. Ann Dermatol Venereol. 1990;117:123-5. 132. Scaparro E, Quadri G, Virno G, Orifici C, Milani M. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol. 2001 Apr;144(4):854-7. 133.Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges. 2003;1:952-8. 134. Yu C SM, Stevens G, Liskanich R, Horowitz D. Isotretinoin as monotherapy for sebaceous hyperplasia. J Drugs Dermatol. 2010;9:699-701. 135. Barzilai A, David M, Trau H, Hodak E. Seborrheic dermatitis-like eruption in patients taking isotretinoin therapy for acne: retrospective study of five patients. Am J Clin Dermatol. 2008;9:255-61.
  97. Ana Luisa Sobral Bittencourt Sampaio Rua Almirante João Cândido Brasil, 72/102 - Tijuca 20511-020 Rio de Janeiro, RJ E-mail: analuisasbs@gmail.com Como citar este artigo/How to cite this article: Sampaio ALB, Mameri A, Jeunon T, Ramos-e-Silva M, Nunes AP, Carneiro S. Dermatite seborreica. An Bras Dermatol. 2011;86(6):1061-74.

Cited by

Sorted by citations

Authors
Sampaio, A. L. S. B., Mameri, Â. C. A., Vargas, T. J. D. S., Ramos-e-Silva, M., Nunes, A. P., & Carneiro, S. C. D. S.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • Clínica Medicina Especializada, Brasil
  • Hospital Geral de Bonsucesso (BR)
  • Universidade Federal do Rio de Janeiro, Brasil
ORCID
Venue
Anais Brasileiros de Dermatologia
Publisher
FapUNIFESP (SciELO)
Published
2011-12
Volume
86
Issue
6
Pages
1061-1074
ISSN
0365-0596 (ISSN-L)
DOI
10.1590/s0365-05962011000600002
OpenAlex
W3209065031
Cited by
103
References
3
Citations by year
2026: 6 · 2025: 5 · 2024: 9 · 2023: 6 · 2022: 11 · 2021: 11 · 2020: 12 · 2019: 12 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 6 · 2013: 6 · 2012: 3
FWCI
3.60
Type
journal article
Language
pt
Open access
Licence
cc-by-nc
Locations
  • Anais Brasileiros de Dermatologia (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • Americanae (AECID Library) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Universidade Federal do Rio de Janeiro
Topics
  • Health Sciences › Medicine › Epidemiology › Nail Diseases and Treatments
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Urology › Hair Growth and Disorders
Keywords
seborrheic dermatitis, Malassezia, pathogenesis, unsaturated fatty acids, immunogenetics, clinical forms, treatment, prevalence, HIV, neurological disorders
MeSH terms
Acquired Immunodeficiency Syndrome, Dermatomycoses, Diagnosis, Differential, Humans, Malassezia, Dermatitis, Seborrheic, HIV Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review